Cyto-Facto

Release Date: Aug. 28. 2023

Shin Kawamata, MD, PhD
CEO
Cyto-Facto Inc.
TRI 3F, 1-5-4, Minatojima-Minami-machi, Chuo-ku, Kobe-City,
650-0047, Japan

# Cyto-Facto Inc. has Raised 300 Million Yen Through Third-Party Allocation Shares

Cyto-Fact Co., Ltd. (Head Office: Chuo-ku, Kobe-City, CEO: Shin Kawamata, hereinafter referred to as CF), which conducts CMO/CDMO business specializing in gene and cell therapy, has raised a total of 300 million yen through the third-party allocation of shares to D3 Bio-Healthcare Fund Investment Limited Partnership No.1 (D3 LLC.: Managing Partner, Tomoya Nagata) and loans from financial institutions.

Objectives of fundraising:

## (1) Expansion of domestic contract manufacturing for CAR-T cell therapies

As the number of new CAR-T products developed by foreign/domestic pharmaceutical companies against solid tumor treatment are expected to be approved and launched in the next 5 to 10 years. The demand for CMOs and CDMOs specialized in cell and gene therapy products, including CAR-T, targeting the Asia-Pacific region is expected to increase. In response to this demand, CF aims to further expand orders and customers by leveraging CF's knowledge and experience specialized in cell and gene therapy manufacturing.

## (2) Expansion of Business Portfolio

There are almost no GMP facilities or companies that can produce viral vectors, which are essential for CAR-T production, and AAV (adeno-associated virus) for gene therapy as commercial products in Japan. CF plans to expand its business portfolio by advancing the construction of viral vector manufacturing facilities and developing an integrated CDMO business in the field of gene and cell therapy in Japan and the Asia-Pacific region.

## (3) Expanding Sales of Integrated Manufacturing Control System

As the manufacturing process of cell and gene therapy products has not yet been industrialized and digitized, a large part of the manufacturing process is still handled manually

with paper documents, causing high costs and inaccuracy in the process implementation of cell and gene therapy products. In order to overcome this situation, CF has developed the all-in-one functional modules with ERP, MES and LIMS systems with all records related to manufacturing, which can be introduced to the manufacturing site in a short time and at low cost. This system is a cloud-type DX system with robust quality assurance and data integrity through process coordination and visualization.

In the field of cell and gene therapy manufacturing, where electronic systemization lags far behind other industries, the introduction of the DX system developed by CF will simplify the complicated process flow of autologous/allogeneic cell manufacturing and quality assurance system. In addition, it could lead to a significant reduction in material and labor costs in the manufacturing cost.

We have already introduced our DX system on "in house" manufacturing process in CF, and start to sell and introduce not only to major foreign/domestic pharmaceutical companies, but also to biotec companies and CMO/CDMO companies in the global market.

END

**About Cyto-Facto Inc:**

Cyto-Facto Inc. was established in Kobe, Japan as the first spin-out company from the Foundation of Biomedical Research and Innovation at Kobe (FBRI) (its predecessor, the Research and Development Center of Cell Thrapy in FBRI) to fulfill social responsibility and social implementation of research and development achievements in the field of cell and gene therapy.

As a CMO/CDMO specializing in the commercial product of cell and gene therapy products, Cyto-Facto is the first Asian company to manufacture commercial CAR-T products under PIC/S GMP. Cyto-Facto has accumulated experience in manufacturing technology know-how and has launched several cell & gene manufacturing pipelines, including CAR-T, iPS-based cells and mesenchymal stem cells (MSCs) of various development stages.

**CEO:**
Shin Kawamata, MD, PhD
**Address:**
TRI 3F, 1-5-4, Minatojima-Minami-machi, Chuo-ku, Kobe-City, 650-0047, Japan
**WEB Site:**
https://www.cytofacto.com/

Cyto-Facto

**For inquiries, please contact**
Takeshi Ito,
Human Resources & General Affairs
PHONE: +81-78-304-5230
E-mail: info@cytofacto.com